M
Marie-Paule Lebitasy
Publications - 10
Citations - 1473
Marie-Paule Lebitasy is an academic researcher. The author has contributed to research in topics: Lung cancer & Population. The author has an hindex of 8, co-authored 10 publications receiving 1251 citations.
Papers
More filters
Journal ArticleDOI
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gérard Zalcman,Gérard Zalcman,Julien Mazieres,Jacques Margery,Laurent Greillier,Clarisse Audigier-Valette,Denis Moro-Sibilot,Olivier Molinier,Romain Corre,Isabelle Monnet,Valérie Gounant,Frédéric Rivière,H. Janicot,Radj Gervais,Chrystele Locher,Bernard Milleron,Quan Tran,Marie-Paule Lebitasy,Franck Morin,Christian Creveuil,Jean-Jacques Parienti,Arnaud Scherpereel +21 more
TL;DR: Addition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease.
Journal ArticleDOI
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Elisabeth Quoix,Gérard Zalcman,Jean-Philippe Oster,Virginie Westeel,Eric Pichon,Armelle Lavolé,Jérôme Dauba,Didier Debieuvre,Pierre-Jean Souquet,Laurence Bigay-Game,Eric Dansin,Michel Poudenx,Olivier Molinier,Fabien Vaylet,Denis Moro-Sibilot,Dominique Herman,Jaafar Bennouna,Jean Trédaniel,Alain Ducoloné,Marie-Paule Lebitasy,Laurence Baudrin,Silvy Laporte,Bernard Milleron +22 more
TL;DR: Despite increased toxic effects, platinum-based doublet chemotherapy was associated with survival benefits compared with vinorelbine or gemcitabine monotherapy in elderly patients with NSCLC and the current treatment paradigm for these patients should be reconsidered.
Journal ArticleDOI
Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
Marie Wislez,Martine Antoine,Laurence Baudrin,Virginie Poulot,Agnes Neuville,Maryvonne Pradere,Elisabeth Longchampt,Sylvie Isaac-Sibille,Marie-Paule Lebitasy,Jacques Cadranel +9 more
TL;DR: It was demonstrated that demographic data, clinical characteristics and stage at presentation did not distinguish between the two subtypes of ADC-BAC, and only mucinous tumors appeared to be resistant to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).
Journal ArticleDOI
Specific features of non-small cell lung cancer in women: a retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997
TL;DR: Gender differences in smoking exposure, presentation, histological distribution, treatment modalities, and survival, according to sex in lung cancer patients diagnosed in France between 1982 and 1997 are emphasized.
Journal ArticleDOI
Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994
TL;DR: Survival time has truly improved as ‘state of the art’ management of SCLC has changed, and disease extent, clinical trial participation, period, type of chemotherapy, and mediastinal irradiation in LD were significant.